MX167579B - Procedimiento para la preparacion de un producto lactoserico - Google Patents

Procedimiento para la preparacion de un producto lactoserico

Info

Publication number
MX167579B
MX167579B MX027001A MX2700184A MX167579B MX 167579 B MX167579 B MX 167579B MX 027001 A MX027001 A MX 027001A MX 2700184 A MX2700184 A MX 2700184A MX 167579 B MX167579 B MX 167579B
Authority
MX
Mexico
Prior art keywords
citrate
procedure
preparation
dairy product
phosphate
Prior art date
Application number
MX027001A
Other languages
English (en)
Inventor
Olivier De Rham
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4237743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX167579(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of MX167579B publication Critical patent/MX167579B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1425—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of whey, e.g. treatment of the UF permeate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1427—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by dialysis, reverse osmosis or hyperfiltration, e.g. for concentrating or desalting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/146—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by ion-exchange
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A23J3/08—Dairy proteins

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Water Supply & Treatment (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dairy Products (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Peptides Or Proteins (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Braking Arrangements (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

La presente invención se refiere a procedimiento para la preparación de un producto lactosérico que contiene en forma estable frente al calor, un pH neutro, las proteínas del suero láctico, caracterizado por prepararse una solución acuosa que contiene en forma no insolubilzada las proteínas del suero láctico y ajustarse las concentraciones de Ca, de Mg, de citrato y/o de fosfato en la solución, los mismo que el pH de ésta, de modo que se satisfagan las relaciones (Ca + Mg - citrato) 0 mM para 5,4pH6,2; (ca + Mag - citrato) 4 mM para 6,2 pH7,2 y (ca + Mag - citrato - fosfato) 4 mM para 7,2 pH 9,0.
MX027001A 1983-05-13 1984-05-10 Procedimiento para la preparacion de un producto lactoserico MX167579B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH261583 1983-05-13

Publications (1)

Publication Number Publication Date
MX167579B true MX167579B (es) 1993-03-30

Family

ID=4237743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX027001A MX167579B (es) 1983-05-13 1984-05-10 Procedimiento para la preparacion de un producto lactoserico

Country Status (17)

Country Link
US (1) US4748034A (es)
EP (1) EP0126290B2 (es)
JP (1) JPS59216544A (es)
AT (1) ATE24658T1 (es)
AU (1) AU564405B2 (es)
CA (1) CA1200416A (es)
DE (1) DE3461886D1 (es)
DK (1) DK235584D0 (es)
ES (1) ES532469A0 (es)
GB (1) GB2139630B (es)
HK (1) HK73787A (es)
KE (1) KE3728A (es)
MX (1) MX167579B (es)
MY (1) MY100729A (es)
NZ (1) NZ208086A (es)
SG (1) SG35687G (es)
ZA (1) ZA843213B (es)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672230A5 (es) 1987-10-15 1989-11-15 Nestle Sa
FR2634104B1 (fr) * 1988-07-18 1991-10-18 Union Coop Agricole Hydrolysat partiel de proteines de lactoserum, procede enzymatique de preparation de cet hydrolysat, et aliment lacte dietetique hypoallergenique le contenant
DE4002204A1 (de) * 1990-01-26 1991-08-01 Westfalen Milchwerke Diaetetisches nahrungsmittel fuer patienten mit niereninsuffizienz
NL9001692A (nl) * 1990-04-26 1991-11-18 Cooeperatieve Melkproductenbed Werkwijze voor de bereiding van een olie-in-water emulsie.
JP3065116B2 (ja) * 1991-02-25 2000-07-12 株式会社第一化成 透明な乳清タンパク質加工品の製造法
JP3059595B2 (ja) * 1992-11-20 2000-07-04 森永乳業株式会社 沈澱を生じない乳清蛋白質分解物の製造法
US5350590A (en) * 1992-12-15 1994-09-27 Beatreme Foods Inc. Protein fat replacer and method of manufacture thereof
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
ES2374621T3 (es) 1997-04-02 2012-02-20 The Brigham And Women's Hospital, Inc. Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica.
CA2333931C (en) 1998-07-15 2013-09-03 Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6106874A (en) * 1998-11-18 2000-08-22 Abbott Laboratories Calcium fortified juice-based nutritional supplement and process of making
KR100815661B1 (ko) 2000-02-17 2008-03-20 웰치 후드스, 인코포레이티드 칼슘-강화된 포도 기재 제품 및 그의 제조 방법
WO2001066772A2 (en) 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
JP2003530432A (ja) * 2000-04-12 2003-10-14 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患の治療
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2001277230A1 (en) * 2000-08-01 2002-02-13 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution andparticles made thereby
RU2174756C1 (ru) * 2000-09-18 2001-10-20 Борисов Александр Борисович Пищевой продукт
DE10062056A1 (de) * 2000-12-15 2002-07-04 Henkel Ecolab Gmbh & Co Ohg Verfahren zur Reinigung von Ionenaustauscher-Kunststoffharzen
EP1992335A1 (en) * 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
ES2291406T3 (es) * 2001-11-26 2008-03-01 Nestec S.A. Composicion nutritiva auto-estable, que contiene proteina de suero lacteo, intacta, procedimiento de fabricacion y uso.
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
EP2284535A1 (en) 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparins
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
JP3833129B2 (ja) * 2002-03-19 2006-10-11 株式会社Ａｄｅｋａ 濃縮牛乳状組成物
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
MXPA05007154A (es) 2002-12-30 2005-09-21 Nektar Therapeutics Atomizador prepeliculizacion.
US7399496B2 (en) * 2003-02-07 2008-07-15 Glanbia Nutritionals (Ireland) Limited Hydrolyzed whey protein compositions
SI1897548T1 (sl) 2003-02-28 2013-12-31 The Johns Hopkins University Regulacija celic T
WO2005019819A1 (en) 2003-08-20 2005-03-03 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
WO2004111199A2 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7355593B2 (en) * 2004-01-02 2008-04-08 Smart Technologies, Inc. Pointer tracking across multiple overlapping coordinate input sub-regions defining a generally contiguous input region
US20050163887A1 (en) * 2004-01-23 2005-07-28 Land O' Lakes, Inc. Method of producing heat stable whey protein and products made therefrom
NZ550944A (en) * 2004-04-02 2009-12-24 Univ Tennessee Res Foundation Dairy components effective for fat loss
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
EP2298897B1 (en) * 2004-09-02 2013-08-14 Yale University Regulation of oncogenes by microRNAs
WO2006034454A1 (en) * 2004-09-23 2006-03-30 The Trustees Of The University Of Princeton Bcl-2 family member and bh-3 only proteins for use in development of peptidomimetics
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
NZ537456A (en) * 2004-12-24 2007-10-26 Fonterra Co Operative Group Whey products and a process for preparing a modified whey protein concentrate
EP1843734A4 (en) * 2005-02-03 2008-09-10 Signum Biosciences Inc COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
KR101317661B1 (ko) * 2005-02-25 2013-10-15 테트랄로직 파마슈티칼스 코포레이션 이량체성 ｉａｐ 억제제
WO2006110731A2 (en) * 2005-04-11 2006-10-19 University Of Tennessee Research Foundation Stable dairy components effective for fat loss
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
EP1906972B1 (en) 2005-07-19 2013-09-11 The University of Tennessee Research Foundation LPA2 receptor agonist for treating diarrhea
NZ565953A (en) 2005-07-27 2012-01-12 Univ Florida Small compounds that correct protein misfolding and uses thereof
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
AU2006279929A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
AU2006320327A1 (en) * 2005-12-01 2007-06-07 Duke University Compounds and methods for inhibiting apoptosis
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049563B1 (en) 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
WO2008060791A2 (en) * 2006-10-13 2008-05-22 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
EP2099911A2 (en) * 2007-01-11 2009-09-16 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
AU2008262252B2 (en) 2007-06-08 2013-09-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
JP2009000091A (ja) * 2007-06-25 2009-01-08 Sanei Gen Ffi Inc 抱気性乳清タンパク質の調製方法及び該方法によって調製される食品
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
US20090233858A1 (en) * 2008-02-26 2009-09-17 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
EP2257626A2 (en) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
CA2723716A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
WO2010033531A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
EP2331103A1 (en) * 2008-09-22 2011-06-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Nuclear factor kappa b pathway inhibitor composition and use of same
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
EP2421899B1 (en) 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
ES2675236T3 (es) 2009-04-30 2018-07-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Schweinfurthinas y usos de las mismas
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
IN2012DN00352A (es) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKINE COMPOSITIONS AND METHODS OF USE
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
CN102791742B (zh) * 2010-01-19 2014-12-24 动量制药公司 评价肝素制剂
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
CA2818992C (en) 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
KR20140020900A (ko) 2011-02-03 2014-02-19 미르나 테라퓨틱스 인코포레이티드 Ｍｉｒ―34의 합성 모방체
CA2826043A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012125623A2 (en) 2011-03-14 2012-09-20 Ludwig Institute For Cancer Research Ltd. Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
IL285335B2 (en) 2011-04-08 2023-12-01 Us Health Chimeric antigen receptors against epidermal growth factor receptor variant III and their use in cancer treatment
US20140287043A1 (en) 2011-04-21 2014-09-25 Trustees Of Tufts College Compositions and methods for stabilization of active agents
JP6068457B2 (ja) 2011-06-14 2017-01-25 ビカム ファーマスーティカルス，インコーポレイテッド 化合物及び組成物
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013020044A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of fibrosis using microrna-19b
US9499464B2 (en) 2011-10-19 2016-11-22 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
IN2014CN02906A (es) 2011-10-20 2015-07-03 Us Health
AU2012346214B2 (en) 2011-11-30 2017-09-14 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2785178B1 (en) 2011-12-01 2019-05-01 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA3209571A1 (en) 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
WO2013162828A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
CN110511278A (zh) 2012-05-07 2019-11-29 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
JP5879437B2 (ja) * 2012-06-15 2016-03-08 森永乳業株式会社 改質ホエイ組成物の製造方法、およびカルシウム増強改質ホエイ組成物の製造方法
US9119858B2 (en) 2012-08-21 2015-09-01 Genesys Research Institute, Inc. Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
WO2014065961A1 (en) 2012-10-24 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
DK2730170T3 (en) 2012-11-13 2016-05-30 Dmk Deutsches Milchkontor Gmbh Allergen-free food compositions
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
WO2014093726A1 (en) 2012-12-12 2014-06-19 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating portal hypertension
US9921224B2 (en) 2013-03-14 2018-03-20 Children's Medical Center Corporation Use of CD36 to identify cancer subjects for treatment
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
ES2935659T3 (es) 2013-03-15 2023-03-09 Tufts College Composiciones de seda de bajo peso molecular y composiciones de seda estabilizadoras
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US20160052985A1 (en) 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
WO2014205516A1 (en) 2013-06-25 2014-12-31 The Walter And Eliza Hall Institute Of Medical Research Method of treating intracellular infection
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
EP3060238A4 (en) 2013-10-21 2017-06-07 Salk Institute for Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
RU2701346C1 (ru) 2013-12-06 2019-09-25 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
RU2668155C1 (ru) 2013-12-16 2018-09-26 Нестек С.А. Вновь идентифицированные пептиды для применения при индукции толерантности при пероральном введении у молодых млекопитающих
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
EP4154901A1 (en) 2014-03-26 2023-03-29 The Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
EP3721875B1 (en) 2014-05-09 2023-11-08 Yale University Particles coated with hyperbranched polyglycerol and methods for their preparation
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
WO2016044383A1 (en) 2014-09-17 2016-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
CN107849117B (zh) 2015-06-05 2022-08-26 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
EP3831844B1 (en) 2015-06-26 2024-03-13 Prindex S.r.l. Diagnosis and therapy of multiple sclerosis
WO2017004142A1 (en) 2015-06-29 2017-01-05 Children's Medical Center Corporation Treatment for myopathy
CN108289928A (zh) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
BR112018010659B1 (pt) * 2015-12-18 2022-06-14 Société des Produits Nestlé S.A. Composição termicamente esterilizada, seu processo para sua preparação, e usos de proteína de soro do leite.
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
EP3405494A1 (en) 2016-01-20 2018-11-28 The Scripps Research Institute Ror2 antibody compositions and related methods
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
CN109310626A (zh) 2016-04-19 2019-02-05 美利坚合众国,由健康及人类服务部部长代表 革兰氏阴性种治疗特应性皮炎的用途
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
WO2017198631A1 (en) 2016-05-16 2017-11-23 Istituto Nazionale Di Genetica Molecolare - Ingm Markers selectively deregulated in tumor-infiltrating regulatory t cells
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
WO2018005799A1 (en) 2016-06-29 2018-01-04 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018005759A1 (en) 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
MY190407A (en) * 2016-07-15 2022-04-21 Arla Foods Amba Method of producing concentrated or dried acid-gellable whey protein aggregates, and related compositions and food products
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
EP3655437A1 (en) 2017-07-20 2020-05-27 NBE-Therapeutics AG Human antibodies binding to ror2
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
WO2019189350A1 (ja) * 2018-03-30 2019-10-03 雪印メグミルク株式会社 κ－カゼイングリコマクロペプチドを含む組成物の製造方法
US10973841B2 (en) 2018-05-11 2021-04-13 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
CN109045278B (zh) * 2018-07-09 2022-06-21 苏州恒瑞健康科技有限公司 一种稳定的乳蛋白质液态体系及其应用
US11266617B2 (en) 2018-10-16 2022-03-08 Massachusetts Institute Of Technology Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
EP3867365A1 (en) 2018-10-19 2021-08-25 Board of Regents, The University of Texas System Engineered long interspersed element (line) transposons and methods of use thereof
MX2021006182A (es) 2018-12-19 2021-06-18 Nestle Sa Composicion para prevenir o reducir la perdida de agua transepidermica y mejorar la funcion de barrera de la piel.
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
BR112021013824A2 (pt) 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
MX2021009184A (es) 2019-01-30 2021-11-12 Janssen Pharmaceutica Nv Métodos para tratar cáncer de próstata basado en subtipos moleculares.
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
EP3952886A1 (en) 2019-04-10 2022-02-16 Elevatebio Technologies, Inc Flt3-specific chimeric antigen receptors and methods of using the same
AU2020280105A1 (en) 2019-05-22 2022-01-20 Massachusetts Institute Of Technology Circular RNA compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
KR20220040483A (ko) 2019-07-26 2022-03-30 얀센 바이오테크 인코포레이티드 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
WO2021019386A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Anti-hk2 chimeric antigen receptor (car)
US20220280656A1 (en) 2019-07-31 2022-09-08 Yale University Compositions and methods for treating sickle cell disease
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
MX2022001985A (es) 2019-08-16 2022-05-19 Janssen Biotech Inc Células inmunitarias terapéuticas con función mejorada y métodos para elaborarlas.
CA3161825A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
CA3166030A1 (en) * 2019-12-30 2021-07-08 Arla Foods Amba Method of producing dense whey protein nanogels, the resulting whey protein nanogels or nanogel compositions, and food products containing such whey protein nanogels or nanogel compositions
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
EP4117715A1 (en) 2020-03-13 2023-01-18 Janssen Biotech, Inc. Materials and methods for binding siglec-3/cd33
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
CN116322788A (zh) 2020-05-19 2023-06-23 奥纳治疗公司 环状rna组合物和方法
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN116615256A (zh) 2020-10-16 2023-08-18 乔治亚大学研究基金会 糖缀合物
AU2022244453A1 (en) 2021-03-24 2023-11-09 Janssen Biotech, Inc. Antibody targeting cd22 and cd79b
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
TW202334080A (zh) 2021-11-08 2023-09-01 美商歐納醫療公司 用於遞送環狀聚核苷酸之脂質奈米粒子組合物
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1085380A (en) * 1913-03-28 1914-01-27 Adam Thomas Bell Whey emulsion.
US1609617A (en) * 1926-06-15 1926-12-07 William O Frohring Method of increasing the coagulating point of milk
US1954769A (en) * 1930-12-08 1934-04-10 M & R Dietetic Lab Inc Treating milk products
US2570231A (en) * 1946-01-04 1951-10-09 Hansen Francis Frederick Condensed milk composition and its preparation
US2555514A (en) * 1947-01-20 1951-06-05 Golden State Company Ltd Whey product derived from milk and process of producing same
FR1523106A (fr) * 1962-06-15 1968-05-03 Afico Sa Lait en poudre pour nourrissons et son procédé de fabrication
DE1692294A1 (de) * 1966-09-14 1971-07-29 United Brands Co Verfahren zur Stabilisierung kondensierter Milch
US3791283A (en) * 1970-08-28 1974-02-12 Gen Foods Corp Method for producing heat and acid stable whey protein material
DE2138277C2 (de) * 1971-07-30 1982-09-16 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Verfahren zur Herstellung eines Molkeeiweißkonzentrates
CH556143A (fr) * 1972-09-11 1974-11-29 Nestle Sa Procede de preparation d'une fraction soluble des proteines du petit lait.
NL7603369A (en) * 1976-03-31 1977-10-04 Stichting Bedrijven Van Het Selective removal of inorganic ions from aq. protein concentrates - by ultrafiltration and diafiltration at controlled pH
FR2391653A1 (fr) * 1977-05-23 1978-12-22 Nestle Sa Soc Ass Tech Prod Procede de traitement du lactoserum
NL181326C (nl) * 1979-11-20 1987-08-03 Stichting Bedrijven Van Het Werkwijze voor de bereiding van voedingsmiddelen waarin een in water oplosbare gedenatureerde wei-eiwitsamenstelling wordt opgenomen alsmede werkwijze ter bereiding van oplosbare gedenatureerde wei-eiwitsamenstellingen.
JPS603814B2 (ja) * 1981-10-02 1985-01-30 協和醗酵工業株式会社 改質ホエ−蛋白貿の製造法
US4460615A (en) * 1981-10-02 1984-07-17 Kyowa Hakko Kogyo Kabushiki Kaisha Process for improving the quality of whey protein
US4497836A (en) * 1982-08-06 1985-02-05 Dairy Technology Ltd. Modified whey product and process including ultrafiltration and demineralization

Also Published As

Publication number Publication date
DK235584D0 (da) 1984-05-11
NZ208086A (en) 1986-06-11
ES8506983A1 (es) 1985-09-01
ATE24658T1 (de) 1987-01-15
ES532469A0 (es) 1985-09-01
DE3461886D1 (en) 1987-02-12
EP0126290A1 (fr) 1984-11-28
GB2139630B (en) 1987-01-07
US4748034A (en) 1988-05-31
GB2139630A (en) 1984-11-14
AU2755184A (en) 1984-11-15
GB8411196D0 (en) 1984-06-06
SG35687G (en) 1988-09-23
EP0126290B2 (fr) 1994-03-30
AU564405B2 (en) 1987-08-13
MY100729A (en) 1991-01-31
CA1200416A (en) 1986-02-11
KE3728A (en) 1987-06-05
EP0126290B1 (fr) 1987-01-07
JPS646739B2 (es) 1989-02-06
HK73787A (en) 1987-10-16
ZA843213B (en) 1984-12-24
JPS59216544A (ja) 1984-12-06

Similar Documents

Publication Publication Date Title
MX167579B (es) Procedimiento para la preparacion de un producto lactoserico
MX162265A (es) Procedimiento mejorado para la preparacion de acido 4-dimetilamino-1-hidro-xibutano-1,1-difosfonico
PT84820B (pt) Processo para a preparacao de bebidas de sumo de frutos e de concentrados de sumo com suplemento nutritivo de calcio
PH23256A (en) A process for the preparation of quinolone carboxylic acid derivatives
AU587365B2 (en) Pasteurized human fibrinogen (HF), a process for its preparation and its use
ES2027744T3 (es) Procedimiento de preparacion de un producto lactoserico de alergenicidad reducida.
FR2594846B1 (fr) Procede de preparation de la serum albumine humaine mature
IE812740L (en) Water-soluble betalactoglobulin
AU1141288A (en) Production of proteins in active forms
CA2040496A1 (en) Method for preparing an aqueous food supplement for cattle and thus prepared food supplement
ES543317A0 (es) Procedimiento para la preparacion de una leche descremada
IE801358L (en) Gelling of whey proteins.
ES2069212T3 (es) Procedimiento para la preparacion de una proteina transparente del suero de la leche ajustada y un producto de proteina del suero de la leche ajustada.
FR2670206B1 (fr) Procede de preparation de derives de l'acide dihydroxy-3,5 pentanouique.
ES8203573A1 (es) Procedimiento de fabricacion de un queso en polvo pasteuri- zado
HUT41375A (en) Process for producing cristalline glutaminic acid, first of all as monosodium salt, and process for producing salts and organic concentrate produced during the process
JPS5685250A (en) Preparation of novel protein material
ES8405359A1 (es) Procedimiento para preparar derivados farmaceuticamente aceptables de 2-dietilamino-metiletil-cis-1-hidroxi-(biciclohexil)-2-carboxilato.
JPS5685251A (en) Preparation of novel protein material
DE3364501D1 (en) Process for the preparation of delipidated lactoserum proteins
ZA885785B (en) Process for the preparation of n6-benzyloxycarbonyl-2,6-diaminopimelamic acid in the l,l or d,d or racemic forms
JPS5754557A (en) Preparation of meat-like food containing blood protein
RU93032908A (ru) Способ получения мягкого сыра
ES8303048A1 (es) Procedimiento de fabricacion de pienso para ganaderia.